ClariTrial — AI Clinical Trial Intelligence

Explore/GLP-1 agonist obesity diabetes trials recruiting

Status

Phase

41 results for “GLP-1 agonist obesity diabetes trials recruiting”

Page 1 of 3

NCT06987903

Recruiting

Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery

N/ABariatric Surgery and Physical ActivityObesity/TherapyBariatric Surgery Complications

Pre- and post-operative physical exercise programmePre- and post-operative respiratory physiotherapy

Fundacin Biomedica Galicia Sur132 participants1 site · SpainCompletes May 2026

CT.gov Full analysis →

NCT05340868

Recruiting

Genetics of the Acute Response to Oral Semaglutide

N/APreDiabetesPrediabetic StateObesity

Semaglutide Pill

Medical University of Bialystok1,000 participants1 site · PolandCompletes Dec 2025

CT.gov Full analysis →

NCT06132477

Recruiting

Impact GLP-1 Agonists Following Bariatric

Phase 4Morbid ObesityMetabolic SyndromeDiabetes Mellitus

GLP-1 receptor agonist

University of Missouri-Columbia150 participants1 site · United StatesCompletes Jul 2028

CT.gov Full analysis →

NCT07351058

Recruiting

A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

Phase 3Obesity or OverweightType 2 Diabetes Mellitus

PlaceboRO7795068

Hoffmann-La Roche1,600 participants3 sites · United StatesCompletes Aug 2028

CT.gov Full analysis →

NCT06937060

Recruiting

Effect of Semaglutide in Patients With Psoriasis and Obesity

Phase 3Psoriasis (PsO)Obesity and Overweight

semaglutide

The University of Hong Kong14 participants1 site · Hong KongCompletes Jul 2026

CT.gov Full analysis →

NCT06446531

Recruiting

Prevention of Progression of Prediabetes, Obesity and CV Risk

Phase 1Pre-DiabetesWeight, BodyCardiovascular Diseases

PlaceboRybelsus TabletJardiance 25Mg Tablet+2 more

The University of Texas Health Science Center at San Antonio64 participants1 site · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT06060392

Recruiting

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

N/ALiver Transplant; ComplicationsDiabete Mellitus

Semaglutide Pill

Medanta, The Medicity, India50 participants1 site · IndiaCompletes Sep 2025

CT.gov Full analysis →

NCT06541509

Recruiting

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Phase 1Phase 2Heart FailureObesity

Semaglutide

University Medical Centre Ljubljana10 participants3 sites · United States, SloveniaCompletes Jul 2025

CT.gov Full analysis →

NCT06706284

Recruiting

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Phase 4Spinal Cord InjuriesType 2 Diabetes

Semaglutide Injectable ProductPlacebo

Marzieh Salehi50 participants2 sites · United StatesCompletes May 2028

CT.gov Full analysis →

NCT06803888

Recruiting

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

Phase 4Obesity and Obesity-related Medical Conditions

Bariatric SurgerySemaglutideTirzepatide

Ali Aminian125 participants1 site · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT07373834

Recruiting

Tirzepatide and Muscle Outcomes in Obesity

N/AObesity (Disorder)

TirzepatidePlacebo

University Medical Centre Ljubljana30 participants1 site · SloveniaCompletes Dec 2026

CT.gov Full analysis →

NCT07364175

Recruiting

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

N/AHypertensionObesity & Overweight

TirzepatideAnti-Hypertensive medications

Cambridge University Hospitals NHS Foundation Trust60 participants1 site · United KingdomCompletes Jan 2027

CT.gov Full analysis →

NCT07457437

Recruiting

Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment

Phase 1Muscle Mass and StrengthObesity & OverweightPhysical Function

Progressive Resistance Exercise Training Program

University of Exeter60 participants1 site · United KingdomCompletes Dec 2027

CT.gov Full analysis →

NCT07104383

Recruiting

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Phase 3Weight Loss

VK2735

Viking Therapeutics, Inc.1,100 participants134 sites · United States, Puerto RicoCompletes Jul 2027

CT.gov Full analysis →

NCT06852391

Recruiting

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Phase 4Obesity (Disorder)

Semaglutide Pen InjectorBehavioural Lifestyle Program (BLP)

McMaster University74 participants1 site · CanadaCompletes Dec 2027

CT.gov Full analysis →

1–15 of 41

Explore/GLP-1 agonist obesity diabetes trials recruiting

Status

Phase

41 results for “GLP-1 agonist obesity diabetes trials recruiting”

Page 1 of 3

NCT06987903

Recruiting

Impact of a Perioperative Physical Exercise and Respiratory Physiotherapy Program on the Patient Undergoing Bariatric Surgery

N/ABariatric Surgery and Physical ActivityObesity/TherapyBariatric Surgery Complications

Pre- and post-operative physical exercise programmePre- and post-operative respiratory physiotherapy

Fundacin Biomedica Galicia Sur132 participants1 site · SpainCompletes May 2026

CT.gov Full analysis →

NCT05340868

Recruiting

Genetics of the Acute Response to Oral Semaglutide

N/APreDiabetesPrediabetic StateObesity

Semaglutide Pill

Medical University of Bialystok1,000 participants1 site · PolandCompletes Dec 2025

CT.gov Full analysis →

NCT06132477

Recruiting

Impact GLP-1 Agonists Following Bariatric

Phase 4Morbid ObesityMetabolic SyndromeDiabetes Mellitus

GLP-1 receptor agonist

University of Missouri-Columbia150 participants1 site · United StatesCompletes Jul 2028

CT.gov Full analysis →

NCT07351058

Recruiting

A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

Phase 3Obesity or OverweightType 2 Diabetes Mellitus

PlaceboRO7795068

Hoffmann-La Roche1,600 participants3 sites · United StatesCompletes Aug 2028

CT.gov Full analysis →

NCT06937060

Recruiting

Effect of Semaglutide in Patients With Psoriasis and Obesity

Phase 3Psoriasis (PsO)Obesity and Overweight

semaglutide

The University of Hong Kong14 participants1 site · Hong KongCompletes Jul 2026

CT.gov Full analysis →

NCT06446531

Recruiting

Prevention of Progression of Prediabetes, Obesity and CV Risk

Phase 1Pre-DiabetesWeight, BodyCardiovascular Diseases

PlaceboRybelsus TabletJardiance 25Mg Tablet+2 more

The University of Texas Health Science Center at San Antonio64 participants1 site · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT06060392

Recruiting

Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus

N/ALiver Transplant; ComplicationsDiabete Mellitus

Semaglutide Pill

Medanta, The Medicity, India50 participants1 site · IndiaCompletes Sep 2025

CT.gov Full analysis →

NCT06541509

Recruiting

Mechanisms of Semaglutide Therapy in Heart Failure Patients

Phase 1Phase 2Heart FailureObesity

Semaglutide

University Medical Centre Ljubljana10 participants3 sites · United States, SloveniaCompletes Jul 2025

CT.gov Full analysis →

NCT06706284

Recruiting

Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

Phase 4Spinal Cord InjuriesType 2 Diabetes

Semaglutide Injectable ProductPlacebo

Marzieh Salehi50 participants2 sites · United StatesCompletes May 2028

CT.gov Full analysis →

NCT06803888

Recruiting

Bariatric Surgery vs. Semaglutide vs. Tirzepatide

Phase 4Obesity and Obesity-related Medical Conditions

Bariatric SurgerySemaglutideTirzepatide

Ali Aminian125 participants1 site · United StatesCompletes Jul 2027

CT.gov Full analysis →

NCT07373834

Recruiting

Tirzepatide and Muscle Outcomes in Obesity

N/AObesity (Disorder)

TirzepatidePlacebo

University Medical Centre Ljubljana30 participants1 site · SloveniaCompletes Dec 2026

CT.gov Full analysis →

NCT07364175

Recruiting

A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

N/AHypertensionObesity & Overweight

TirzepatideAnti-Hypertensive medications

Cambridge University Hospitals NHS Foundation Trust60 participants1 site · United KingdomCompletes Jan 2027

CT.gov Full analysis →

NCT07457437

Recruiting

Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment

Phase 1Muscle Mass and StrengthObesity & OverweightPhysical Function

Progressive Resistance Exercise Training Program

University of Exeter60 participants1 site · United KingdomCompletes Dec 2027

CT.gov Full analysis →

NCT07104383

Recruiting

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Phase 3Weight Loss

VK2735

Viking Therapeutics, Inc.1,100 participants134 sites · United States, Puerto RicoCompletes Jul 2027

CT.gov Full analysis →

NCT06852391

Recruiting

JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity

Phase 4Obesity (Disorder)

Semaglutide Pen InjectorBehavioural Lifestyle Program (BLP)

McMaster University74 participants1 site · CanadaCompletes Dec 2027

CT.gov Full analysis →

1–15 of 41